Isotope imaging for metastatic thyroid cancer

Endocrinology and Metabolism Clinics of North America

Volumn 30, Issue 2, 2001, Pages 469-492

  Haugen, Bryan R ^a   Lin, Eugene C ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; FURIFOSMIN TC 99M; INDIUM 111; IODINE 123; IODINE 131; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PENTETREOTIDE IN 111; PERTECHNETIC ACID TC 99M; RECOMBINANT THYROTROPIN; SOMATOSTATIN RECEPTOR; TETROFOSMIN TC 99M; THALLIUM 201; THALLIUM CHLORIDE TL 201; THYROGLOBULIN; THYROXINE;

HUMAN; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CANCER;

EID: 0034963144     PISSN: 08898529     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8529(05)70195-X     Document Type: Article

References (86)

1. Diagnostic value of technecium-99m methoxyisobutyl isonitrile (99mTc-MIBI) scintigraphy in detecting thyroid cancer metastases: A critical evaluation
2. Position emission tomography with F18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans
3. Uptake of technicium-99m-tetrofosmin, technicium-99m-MIBI and thallium-201 in tumor cell lines
4. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: Contribution for patients with negative radioiodine scan
5. Use of iodine-123 as a diagnostic tracer for neck and whole-body scanning in patients with well-differentiated thyroid cancer
6. Technetium-99m-furofosmin in the follow-up of differentiated thyroid carcinoma
7. Thallium-201 imaging in the follow-up of differentiated thyroid carcinoma
8. Insensitivity of Tc-99m pertechnetate for detecting metastases of differentiated thyroid carcinoma
9. Total-body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer
10. Subcellular distribution and analysis of technicium-99m-MIBI in isolated perfused rat hearts
11. Thallium-201 increases detectability of thyroid cancer metastases
12. 131I
13. 131I whole-body scan
14. Management of patients with differentiated thyroid cancer who have positive serum thyroglobulin levels and negative radioiodine scans
15. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography
16. Clinical utility of technicium-99m methoxybutylisordtrile imaging in differentiated thyroid carcinoma: Comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation
17. The role of iodine-131 and thallium-201 and serum thyroglobulin in the management of differentiated thyroid carcinoma
18. Follow-up of differentiated thyroid cancer: What is the value of FDG and sestamibi in the diagnostic algorithm?
19. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy
20. 201T1 scintigraphy in visualization of suppressed thyroid tissue
21. Fluoro-18-deoxyglucose positron emission tomography in differentiated thyroid cancer
22. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer
23. Imaging in thyroid cancer
24. Tc-99m-tetrofosmin scintigraphy: An alternative scintigraphic method for follow-up of differentiated thyroid carcinoma - Preliminary results
25. Thyroglobulin and low dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma
26. Use of indium-111 pentreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake
27. Fluorine-18-fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicenter study
28. 131I scintiscans and thyroglobulin testing
29. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer
30. Role of thallium-201 total-body scintigraphy in the follow-up of thyroid carcinoma
31. Positron emission tomography for detecting iodine-131 nonvisualised metastases of well-differentiated thyroid carcinoma: Two case reports
32. Follow-up study of postoperative patients with thyroid cancer by thallium-201 scintigraphy and serum thyroglobulin measurement
33. 18F-fluorodeoxyglucose positron emission tomography
34. Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients
35. Imaging of metastases of thyroid carcinoma with fluorine-18-fluorodeoxyglucose
36. Thyrotoxicosis
37. Increased uptake of iodine-131 in metastases of differentiated thyroid carcinoma associated with less severe hypothyroidism following total thyroidectomy
38. The use of technetium-99m pertechnetate in postoperative thyroid carcinoma: A comparative study with iodine-131
39. Technetium-99m-tetrofosmin imaging in thyroid disease: Comparison with Tc-99m-pertechnetate, thallium-201, and Tc-99m-methoxyisobutybdtrile scans
40. Technetium- 99m tetrofosmin imaging of differentiated mixed thyroid cancer
41. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma
42. Relative value of thallium-201 and iodine-131 scans in the detection of recurrence or distant metastases of well-differentiated thyroid carcinoma
43. Technetium-99m-tetrofosmin whole-body scintigraphy in the follow-up of differentiated thyroid carcinoma
44. Comparison of different tracers in follow-up of differentiated thyroid carcinoma
45. Thallium-201 and iodine-131 scintigraphy in differentiated thyroid carcinoma
46. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma
47. Clinical experience with recombinant human thyrotropin (rhTSH) in the management of patients with differentiated thyroid cancer
48. Detection of residual and recurrent thyroid cancer by radionuclide imaging
49. Radioiodine-131 in the diagnosis and treatment of metastatic well-differentiated thyroid cancer
50. 131I (i.e., it does not cause stunning) in differentiated thyroid cancer
51. 131I-negative whole-body scan, and positive thyroglobulin in differentiated thyroid carcinoma: What is being treated?
52. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study)
53. Evaluation of technetium-99m-MIBI scintigraphy in metastatic differentiated thyroid carcinoma
54. 201T1 uptake in thyroid carcinoma
55. Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma
56. Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma
57. I-123 scanning for follow-up of thyroid cancer
58. Pulmonary metastasis of differentiated thyroid carcinoma: Treatment results in 101 patients
59. Technetium-99m-sestamibi scintigraphy compared with thallium-201 in evaluation of thyroid tumors
60. Positive thyroid cancer scintigraphy using technetium-99m methoxyisobutylnitrile
61. 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma
62. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal
63. Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer with detectable serum thyroglobulin levels
64. Detection of thyroid remnant/metastasis without stunning: An ongoing dilemma
65. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan
66. Bone metastases from thyroid carcinoma: Clinical characteristics and prognostic variables in one hundred forty-six patients
67. Thallium-201 scintigraphy in differentiated thyroid cancer: Comparison with radioiodine scintigraphy and serum thyroglobulin determinations
68. Clinical experience with recombinant human thyroid-stimulating hormone (rhTSH): Whole-body scanning with iodine-131
69. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue
70. Complementary role of whole body scan and serum thyroglobulin determination in follow-up of differentiated thyroid carcinoma
71. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest x-rays
72. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma
73. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma
74. 131I ablative therapy
75. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: Implications for diagnosis and therapy
76. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement
77. 201T1 scintigraphy in patients with cold thyroid nodules
78. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases
79. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioidine scintigraphy
80. 201T1 scintigraphy in the postoperative follow-up of differentiated thyroid cancer
81. 131I posttreatment whole-body scans
82. 18F-fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer
83. 131I whole-body scans and elevated serum thyroglobulin levels
84. The use of radioactive iodine in patients with papillary and follicular thyroid cancer
85. The usefulness of iodine-123 whole-body scans in evaluating thyroid carcinoma and metastases
86. 5 and 24 hour I-123 scintigraphy in thyroid cancer